Bausch Health News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

28.09.18	Biotech Stocks Facing FDA Decision In October (RTTNews)
30.08.18	MESO Awaits Next Catalyst, EC Nod For Blincyto, EOLS, BHC To Face FDA In Feb. (RTTNews)
27.08.18	BGNE On Watch, AMRN Gears Up For Big Event, ZLAB Discontinues ZL-3101 (RTTNews)
02.05.11	Teva Pharmaceutical kauft Cephalon (Aktiencheck)
03.03.08	Valeant Pharmaceuticals Divests Asia Region to Invida Pharmaceutical Holdings for $37.8 Million (Businesswire)
28.02.08	Valeant Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results (Businesswire)
04.12.07	Biovail Announces Settlement Agreement Related to Cardizem(R) LA (Businesswire)
23.01.07	Valeant Pharmaceuticals Files Restated Financial Statements and September 30, 2006 Form 10-Q (Businesswire)
22.12.06	Company Announces Acquisition of Research and Development Programs, Hiring of Senior Management Team and Name Change (PR Newswire)
14.12.06	Schering-Plough erwirbt weltweites Lizenzrecht für Pradefovir (Aktiencheck)
12.12.06	Valeant Pharmaceuticals Initiates Infergen(R) Phase 4 Study (Businesswire)
06.12.06	Biovail: CFO Charles Rowland ausgeschieden (Aktiencheck)
04.10.06	Intendis and Valeant Pharmaceuticals Sign Distribution Agreement for Finacea(R), a New Treatment in the UK for Rosacea (PR Newswire)
10.08.06	Biovail verbucht deutlichen Ergebnisnastieg, Aktie vorbörslich gefragt (Aktiencheck)
16.05.06	Valeant Pharmaceuticals Receives FDA Marketing Approval for Cannabinoid Cesamet(TM) (CII) (Businesswire)
04.05.06	Valeant Pharmaceuticals Reports 2006 First Quarter Results; Restructuring Initiative on Track; $20-30 Million in 2006 Cost Savings Targeted (Businesswire)
28.02.06	Valeant Pharmaceuticals Reports Fourth Quarter and Full Year 2005 Results (Businesswire)
15.11.05	Valeant Pharmaceuticals Presents Positive Interim Data on Pradefovir Mesylate at AASLD; 24-Week Interim Results Show Pradefovir Statistically Better Than Hepsera (Businesswire)
03.11.05	Valeant Pharmaceuticals Reports Third Quarter 2005 Results; Revenues Increase 23 Percent; Product Sales Advance 21 Percent (Businesswire)
10.03.05	Biovail Reports Fourth Quarter, Year-End 2004 Financial Results (Businesswire)
01.03.05	Biovail, Depomed Receive Approvable Letter from FDA for Extended-Relea (Businesswire)
24.02.05	Valeant Pharmaceuticals Reports Fourth Quarter and Full Year 2004 Resu (Businesswire)
22.02.05	Biovail Announces $27.6-Million Expansion to Steinbach, Manitoba Manuf (Businesswire)
02.02.05	Valeant Pharmaceuticals to Acquire Xcel Pharmaceuticals; Acquisition E (Businesswire)
05.01.05	Valeant Pharmaceuticals Submits Complete Response to FDA Approvable Le (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Swisscom	527.00	2.33 %	K V
Holcim	95.34	1.21 %	K V
UBS Group	30.42	0.86 %	K V
Roche Hldg G	289.00	0.45 %	K V
Swiss Re	141.65	0.35 %	K V
Givaudan	3’850.00	-1.48 %	K V
Lonza Grp	603.80	-1.50 %	K V
Alcon	82.30	-1.53 %	K V
Geberit	508.00	-1.74 %	K V
Part Grp Hldg	1’386.00	-2.26 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Bausch Health

Aktien Top/Flop

Meistgelesene Nachrichten